课题基金 / 基金详情

PHASE I STUDY OF BMS-188667 IN PATIENTS WITH PSORIASIS VULGARIS

PHASE I STUDY OF BMS-188667 IN PATIENTS WITH PSORIASIS VULGARIS
BMS-188667 在寻常型银屑病患者中的 I 期研究
批准号：
6245653
负责人：
BRIAN JEGASOTHY
金额：
$1.76万
依托单位：
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
依托单位国家：
美国
项目类别：
财政年份：
1997
资助国家：
美国
项目状态：
已结题
起止时间：
1997-03-18 至 1997-11-30
来源：
https://reporter.nih.gov/project-details/6245653
关键词：
artificial immunosuppression clinical research clinical trial phase I dosage drug screening /evaluation human subject human therapy evaluation immunosuppressive intravenous administration longitudinal human study psoriasis skin disorder chemotherapy

项目摘要

项目成果

BRIAN JEGASOTHY的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This is a Phase I:II open-label study assessing the safety, efficacy & biologic activity of BMS-188667 in patients with 10-40% body surface area of psoriasis vulgaris. BMS-188667 is an investigational drug that selectively blocks the second signal in T-cell activation. Increasing evidence suggests that T-cell is involved in the pathogenesis of this disease. Patients will receive four IV doses of BMS-188667 and be evaluated for safety and efficacy in follow-up for a total period of 99 days.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
PHASE III RANDOMIZED TRIAL OF TWO DOSE DA389IL-2 IN CTCL <3 PREVIOUS TREATMENTS
MULTICENTER PHASE 3 TRIAL OF DAB3891L-2 IN CTCL PATIENTS IN STAGE IA-IVA DISEASE
PHASE III RANDOMIZED TRIAL OF TWO DOSE DA389IL-2 IN CTCL <3 PREVIOUS TREATMENTS
PHASE III RANDOMIZED TRIAL OF TWO DOSE DA389IL-2 IN CTCL <3 PREVIOUS TREATMENTS
海外基金